Claims for Patent: 11,925,648

Summary for Patent: 11,925,648

Title:	Solid dosage form having excellent stability
Abstract:	The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.
Inventor(s):	Naoya MIZUTANI, Masayuki Morimoto, Maki Okabe, Masaaki Ito, Go KIMURA
Assignee:	Shionogi and Co Ltd
Application Number:	US17/077,606
Patent Claims:	1. A solid dosage form comprising a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, and an alkali metal chloride, wherein the solid dosage form is in the form of a granule. 2. The solid dosage form according to claim 1, wherein the alkali metal chloride is sodium chloride, potassium chloride, or a combination thereof. 3. The solid dosage form according to claim 1, wherein the alkali metal chloride is sodium chloride. 4. The solid dosage form according to claim 2, further comprising a sugar alcohol, a sugar, or a combination thereof. 5. The solid dosage form according to claim 4, wherein the sugar alcohol, sugar, or combination thereof is one or more substances selected from the group consisting of isomalt, maltitol, mannitol, xylitol, erythritol, sorbitol, lactose, sucrose, fructose, maltose, purified white sugar, and trehalose. 6. The solid dosage form according to claim 1, further comprising a water-soluble polymer. 7. The solid dosage form according to claim 6, wherein the water-soluble polymer is a cellulose-based polymer. 8. The solid dosage form according to claim 7, wherein the cellulose-based polymer is one or more substances selected from the group consisting of hypromellose, hydroxypropyl cellulose, methyl cellulose, carboxymethyl cellulose, carboxymethyl ethyl cellulose, hypromellose phthalate, and hydroxypropyl methyl cellulose acetate succinate. 9. The solid dosage form according to claim 8, wherein the cellulose-based polymer is hypromellose. 10. The solid dosage form according to claim 1, wherein the solid dosage form does not comprise a coating layer. 11. The solid dosage form according to claim 1, further comprising one or more substances selected from the group consisting of hydrated silicon dioxide, light anhydrous silicic acid and talc. 12. The solid dosage form according to claim 1, comprising 1 mg to 80 mg of the compound represented by formula (I): 13. The solid dosage form according to claim 2, further comprising: a cellulose-based polymer; and a sugar, a sugar alcohol, or a combination thereof. 14. The solid dosage form according to claim 13, wherein the compound represented by formula (I) is present in an amount of 1 to 4% by weight based on the total weight of the solid dosage form. 15. The solid dosage form according to claim 14, comprising from 10 mg to 40 mg of the compound represented by formula (I). 16. The solid dosage form according to claim 3, further comprising: talc, hypromellose, mannitol, maltitol, and polyvinyl pyrrolidone. 17. The solid dosage form according to claim 16, wherein the compound represented by formula (I) is present in an amount of 1 to 4% by weight based on the total weight of the solid dosage form. 18. The solid dosage form according to claim 17, comprising from 10 mg to 40 mg of the compound represented by formula (I). 19. The solid dosage form according to claim 3, wherein the compound represented by formula (I) is present in an amount of 1 to 4% by weight; and wherein the solid dosage form further comprises: a flavoring agent, present in an amount of 0.05 to 7.5% by weight based on the total weight of the solid dosage form; a lubricant, present in an amount of 0.01 to 0.5% by weigh based on the total weight of the solid dosage form; a suspending agent, present in an amount of 0.1 to 5% by weight based on the total weight of the solid dosage form; a fluidizing agent, present in an amount of 0.1 to 5% by weight based on the total weight of the solid dosage form; and a binder, present in an amount of 0.25 to 15% by weight based on the total weight of the solid dosage form. 20. The solid dosage form according to claim 19, wherein: the lubricant is talc; the suspending agent is hypromellose; and the binder is polyvinyl pyrrolidone. 21. The solid dosage form according to claim 20, comprising from 10 mg to 40 mg of the compound represented by formula (I). 22. The solid dosage form according to claim 4, comprising mannitol and maltitol.